Rewalk Robotics Ltd
F:2RW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Rewalk Robotics Ltd
F:2RW
|
IL |
|
Canadian Tire Corporation Ltd
OTC:CDNTF
|
CA |
|
C
|
Celestica Inc
DUS:CTW0
|
CA |
Rewalk Robotics Ltd
ReWalk Robotics makes wearable robotic systems that help people with lower-limb mobility problems stand, walk, and train. Its core products are exoskeletons and rehabilitation devices used by people with spinal cord injuries, stroke survivors, and other patients who need help regaining movement. The company also sells related support, training, and service around these devices. Its customers are mainly hospitals, rehabilitation centers, clinics, veterans’ programs, and individual patients who qualify for the equipment. ReWalk earns money by selling or leasing its devices and by providing ongoing service, support, and training. In practice, it sits in a specialized corner of medical technology where the product is not a one-time machine sale but a clinical tool that often needs fitting, education, and after-sales support. That makes the business different from a normal medical device maker. ReWalk is focused on a narrow problem: helping people with serious leg-mobility loss move again with robotic assistance. Its value comes from combining hardware, clinical know-how, and patient support, which gives it a role in the rehab and mobility-care chain rather than a broad consumer or hospital equipment business.
ReWalk Robotics makes wearable robotic systems that help people with lower-limb mobility problems stand, walk, and train. Its core products are exoskeletons and rehabilitation devices used by people with spinal cord injuries, stroke survivors, and other patients who need help regaining movement. The company also sells related support, training, and service around these devices.
Its customers are mainly hospitals, rehabilitation centers, clinics, veterans’ programs, and individual patients who qualify for the equipment. ReWalk earns money by selling or leasing its devices and by providing ongoing service, support, and training. In practice, it sits in a specialized corner of medical technology where the product is not a one-time machine sale but a clinical tool that often needs fitting, education, and after-sales support.
That makes the business different from a normal medical device maker. ReWalk is focused on a narrow problem: helping people with serious leg-mobility loss move again with robotic assistance. Its value comes from combining hardware, clinical know-how, and patient support, which gives it a role in the rehab and mobility-care chain rather than a broad consumer or hospital equipment business.
Strategic shift: Lifeward said the quarter marked an important milestone with the completion of the Oratech acquisition, which it believes strengthens the company’s biomedical platform without adding much near-term operating burden.
Revenue pressure: First-quarter revenue fell to $3.9 million from $5.0 million a year ago, mainly because AlterG shipments were delayed by temporary supply-chain, sourcing and working-capital constraints tied to the manufacturing transition.
ReWalk strength: ReWalk personal exoskeleton sales rose 11% year over year to $1.6 million, helped by reimbursement progress, channel expansion and international sales, with Germany up almost 25% quarter over quarter.
Margins and costs: Gross margin declined to 34.2% from 42.2%, pressured by lower production volumes, freight, tariffs and foreign exchange, while adjusted operating expenses fell 12% year over year.
Balance sheet: Cash and cash equivalents rose to $11.4 million from $2.2 million at year-end, supported by the $10 million convertible note financing and about $6.5 million of cash from the Oratech transaction.
Outlook: Management did not give formal 2026 guidance, but repeatedly said revenue should be similar to 2025 and that AlterG shipments should improve through Q2 and Q3, with the exit rate of the year better than the start.
